Partikula LLC is developing nanoparticles that have size and charge optimized to deliver therapeutic payloads into mitochondria, beginning with two lead programs that aim to disrupt cancer metabolism by using the technology to deliver chemotherapeutic and cytotoxic agents.

Mitochondria drive cellular metabolism. The intracellular organelles are particularly active in cancers, which require substantial amounts of energy to grow. However, selectively hitting mitochondrial targets has proven challenging because drugs must cross multiple membranes.